دورية أكاديمية
أعرض في EDS

Donor selection in allogeneic stem cell transplantation.

التفاصيل البيبلوغرافية
العنوان: Donor selection in allogeneic stem cell transplantation.
المؤلفون: Barriga F; Section of Hematology, Oncology and Stem Cell Transplantation, Pontificia Universidad Católica de Chile, Stem Cell Collection Center, Fundación de Beneficiencia Pública DKMS, Santiago, Chile., Lima ACM; Laboratory of Histocompatibility, Complexo Hospital de Clínicas da Universidade Federal do Paraná, Brazil.
المصدر: Current opinion in hematology [Curr Opin Hematol] 2024 Nov 01; Vol. 31 (6), pp. 261-269. Date of Electronic Publication: 2024 Jul 15.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams And Wilkins Country of Publication: United States NLM ID: 9430802 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-7048 (Electronic) Linking ISSN: 10656251 NLM ISO Abbreviation: Curr Opin Hematol Subsets: MEDLINE
أسماء مطبوعة: Publication: Philadelphia Pa : Lippincott Williams And Wilkins
Original Publication: Philadelphia, PA : Current Science, c1993-
مواضيع طبية MeSH: Donor Selection* , Hematopoietic Stem Cell Transplantation*/methods , Transplantation, Homologous*, Humans ; Histocompatibility Testing ; HLA Antigens/immunology ; HLA Antigens/genetics ; Unrelated Donors ; Hematologic Neoplasms/therapy ; Tissue Donors ; Graft vs Host Disease/prevention & control ; Graft vs Host Disease/etiology
مستخلص: Purpose of Review: Recent progress in human leukocyte antigen (HLA) characterization, increased accrual of unrelated donors and cord blood units, and a new platform for haploidentical transplantation have resulted in the widespread availability of donors for allogeneic hematopoietic stem cell transplantation.
Recent Findings: Advances in HLA typing have identified an increasing number of loci and alleles that are crucial for successful transplantation. Newer HLA A, B, C, DRB1, and DQB1 alleles, DPB1 mismatches, and HLA B leader sequence matching are incorporated into donor selection algorithms. Donor selection is highly relevant because of recently published conflicting studies using different donor types. These studies are largely retrospective and compare patients with different diseases and stages, conditioning regimens, graft versus host disease (GVHD) prophylaxis, and time periods. A broad consensus indicates that the best donor is an available matched sibling, followed by a matched unrelated donor, and then alternative donors such as haploidentical, mismatched unrelated, and cord blood units. This consensus is being challenged by other factors, such as donor age, patient condition, urgency of transplantation, and costs involved.
Summary: In this review, we will analyze the unique characteristics of each donor type, the HLA and non HLA factors that affect donor choices, and the outstanding comparative outcome studies of different donor usage in hematologic malignancies.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
References: Niederwieser D, Baldomero H, Bazuaye N, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of nonidentical family donors. Haematologica 2022; 107:1045–1053.
Mohty M, Malard F. Increasing donor options in allogenic hematopoietic cell transplantation. J Clin Oncol 2021; 39:1951–1954.
Bolon YT, Atshan R, Allbee-Johnson M, et al . Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2022. Available at: http://www.cibmtr.org .
Passweg JR, Baldomero H, Ciceri F, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A report from the EBMT Activity Survey. Bone Marrow Transplant 2023; 58:647–658.
Besse K, Maiers M, Confer D, Albrecht M. On modeling human leukocyte antigen–identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source. Biol Blood Marrow Transplant 2016; 22:410–417.
Evseeva I, Foeken L, Madrigal A. The role of unrelated donor registries in HSCT. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. 7th ed. Cham (CH): Springer; 2019. Chapter 3. PMID: 32091783.
Chowdhury AS, Maiers M, Spellman SR, et al. Existence of HLA-mismatched unrelated donors closes the gap in donor availability regardless of recipient ancestry. Transplant Cell Ther 2023; 29:686.e1–686.e8.
Hammami MB, Verceles JA, Goldfinger M, et al. Improving unrelated donor equity: assessing mismatched donor opportunities with real-world data in a minority-predominant cohort. Transplant Cell Ther 2024; 30:544.e1–544.e8.
Gragert L, Spellman SR, Shaw BE, Maiers M. Unrelated stem cell donor HLA match likelihood in the US registry incorporating HLA-DPB1 permissive mismatching. Transplant Cell Ther 2023; 29:244–252.
Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood 2013; 122:491–498.
Sanchez-Petitto G, Rezvani K, Daher M, et al. Umbilical cord blood transplantation: connecting its origin to its future. Stem Cells Transl Med 2023; 12:55–71.
Scaradavou A, Brunstein CG, Eapen M, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood 2013; 121:752–758.
Saiyin T, Kirkham AM, Bailey AJM, et al. Clinical outcomes of umbilical cord blood transplantation using ex vivo expansion: a systematic review and meta-analysis of controlled studies. Transplant Cell Ther 2023; 29:129.e1–129.e9.
Aversa F, Pierini A, Ruggeri L, et al. The evolution of T cell depleted haploidentical transplantation. Front Immunol 2019; 10:2769.
Kanakry C, Fuchs E, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol 2016; 13:10–24.
Nagler A, Ruggeri A. Haploidentical stem cell transplantation for patients with acute leukemia—an update on behalf of the ALWP of the EBMT. Bone Marrow Transplant 2019; 54: (Suppl 2): 713–718.
Shouval R, Fein JA, Labopin M, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol 2019; 6:e573–e584.
Spellman SR. Hematology 2022—what is complete HLA match in 2022? Hematology Am Soc Hematol Educ Program 2022; 2022:83–89.
Ayuk F, Beelen DW, Bornhäuser M, et al. Relative impact of HLA matching and non HLA donor characteristics on outcomes of allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2018; 24:2558–2567.
Petersdorf EW, Carrington M, O’hUigin C, et al. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. Lancet Haematol 2020; 7:e50–e60.
Verneris MR, Lee SJ, Ahn KW, et al. HLA mismatch is associated with worse outcomes after unrelated donor reduced-intensity conditioning hematopoietic cell transplantation: an analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2015; 21:1783–1789.
Morishima Y, Kashiwase K, Matsuo K, et al. Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. Blood 2015; 125:1189–1197.
Kollman C, Spellman SR, Zhang MJ, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood 2016; 127:260–267.
Horan J, Wang T, Haagenson M, et al. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. Blood 2012; 120:2918–2924.
Shaw BE, Mayor NP, Szydlo RM, et al. Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants. Bone Marrow Transplant 2017; 52:717–725.
Dehn J, Spellman S, Hurley CK, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood 2019; 134:924–934.
Hurley CK, Ng J. Continue to focus clinical decision-making on the antigen recognition domain for the present. Hum Immunol 2019; 80:79–84.
Crivello P, Arrieta-Bolaños E, He M, et al. Impact of the HLA immunopeptidome on survival of leukemia patients after unrelated donor transplantation. J Clin Oncol 2023; 41:2416–2427.
Petersdorf EW, Bengtsson M, Horowitz M, et al. HLA-DQ heterodimers in hematopoietic cell transplantation. Blood 2022; 139:3009–3017.
Watkins B, Qayed M. Novel approaches to acute graft-versus-host disease prevention. Hematology Am Soc Hematol Educ Program 2023; 2023:155–163.
Rappazzo KC, Zahurak M, Bettinotti M, et al. Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose post-transplantation cyclophosphamide. Transplantat Cell Ther 2021; 27:909.e1–909.e6.
Al Malki MM, Tsai NC, Palmer J, et al. Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. Blood Adv 2021; 5:2650–2659.
Jimenez Jimenez AM, Komanduri K, Brown S, et al. Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant. Blood Adv 2022; 6:4491–4500.
Shaw BE, Jimenez-Jimenez AM, Burns LJ, et al. National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide. J Clin Oncol 2021; 39:1971–1982.
Raghunandan S, Gorfinkel L, Bratrude B, et al. Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis. Bone Marrow Transplant 2023; 58:1260–1263.
Admiraal R, Nierkens S, Bierings MB, et al. Individualised dosing of antithymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. Lancet Haematol 2022; 9:e111–e120.
Politikos I, Davis E, Nhaissi M, et al. Guidelines for cord blood unit selection. Biol Blood Marrow Transplant 2020; 26:2190–2196.
Fuchs EJ, McCurdy SR, Solomon SR, et al. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood 2022; 139:1452–1468.
Kharfan-Dabaja MA, Labopin M, Ayala E, et al. Significance of degree of HLA disparity using T-cell replete peripheral blood stem cells from haploidentical donors with posttransplantation cyclophosphamide in AML in first complete hematologic remission: a study of the acute leukemia working party of the EBMT. HemaSphere 2023; 7:e920.
Petersdorf EW, Bengtsson M, De Santis D, et al. Role of HLA-DP expression in graft-versus-host disease after unrelated donor transplantation. J Clin Oncol 2020; 38:2712–2718.
Fleischhauer K, Shaw BE, Gooley T, et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol 2012; 13:366–374.
Arrieta-Bolaños E, Crivello P, Shaw BE, et al. In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance. Blood Adv 2018; 2:1773–1783.
Lorentino F, Sacchi N, Oldani E, et al. Comparative evaluation of biological human leukocyte antigen DPB1 mismatch models for survival and graft-versus-host disease prediction after unrelated donor hematopoietic cell transplantation. Haematologica 2020; 105:e186–e189.
Ruggeri A, De Wreede LC, Müller CR, et al. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation. Haematologica 2023; 108:645–652.
Bettinotti MP. Evolution of HLA testing for hematopoietic stem cell transplantation: importance of the candidate's antibody profile for donor selection. Hum Immunol 2022; 83:721–729.
Lima ACM, Getz J, do Amaral GB, et al. Donor-specific HLA antibodies are associated with graft failure and delayed hematologic recovery after unrelated donor hematopoietic cell transplantation. Transplant Cell Ther 2023; 29:493.e1–493.e10.
Spellman S, Bray R, Rosen-Bronson S, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 2010; 115:2704–2708.
Fuji S, Oshima K, Ohashi K, et al. Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant 2020; 55:722–728.
Zou J, Romee R, Slade M, et al. Untreated donor specific antibodies against HLA are associated with poor outcomes in peripheral blood Haploidentical hematopoietic cell transplantation. Bone Marrow Transplant 2017; 52:898–901.
Lima ACM, Bonfim C, Getz J, et al. Untreated donor-specific HLA antibodies are associated with graft failure and poor survival after haploidentical transplantation with post-transplantation cyclophosphamide in pediatric patients with nonmalignant disorders. Transplant Cell Ther 2022; 28:698.e1–698.e11.
Xie Y, Parekh J, Tang Z, et al. Donor-specific antibodies and primary graft failure in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transplant Cell Ther 2021; 27:687.e1–687.e7.
Ciurea SO, Al Malki MM, Kongtim P, et al. Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv 2021; 5:4031–4043.
Bailén R, Vicario JL, Solán L, et al. Management of donor-specific antibodies in haploidentical transplant: multicenter experience from the Madrid Group of Hematopoietic Transplant. Front Immunol 2021; 12:674658.
Ciurea SO, Al Malki MM, Kongtim P, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in Haploidentical hematopoietic cell transplantation. Bone Marrow Transplant 2020; 55:12–24.
Shaw BE, Logan BR, Spellman SR. Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most. Biol Blood Marrow Transplant 2018; 24:1049–1056.
DeZern AE, Franklin C, Tsai HL, et al. Relationship of donor age and relationship to outcomes of Haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv 2021; 5:1360–1368.
Ayuk F, Zabelina T, Wortmann F, et al. Donor choice according to age for allo-SCT for AML in complete remission. Bone Marrow Transplant 2013; 48:1028–1032.
Karam E, Laporte J, Solomon SR, et al. Who is a better donor for recipients of allogeneic hematopoietic cell transplantation: a young HLA-mismatched haploidentical relative or an older fully HLA-matched sibling or unrelated donor? Biol Blood Marrow Transplant 2019; 25:2054–2060.
Abid MB, Estrada-Merly N, Zhang MJ, et al. Younger matched unrelated donors confer decreased relapse risk compared to older sibling donors in older patients with B cell acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation. Transplant Cell Ther 2023; 29:611–618.
Nakasone H, Remberger M, Tian L, et al. Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. Haematologica 2015; 100:1477–1485.
Eberhardt KA, Jung V, Knops E, et al. CMV-IgG preallogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality. Bone Marrow Transplant 2023; 58:639–646.
Atilla E, Atilla PA, Bozdağ SC, Demirer T. A review of infectious complications after Haploidentical hematopoietic stem cell transplantations. Infection 2017; 45:403–411.
Khimani F, Ranspach P, Elmariah H, et al. Increased infections and delayed CD4+ T cell but faster B cell immune reconstitution after post-transplantation cyclophosphamide compared to conventional GVHD prophylaxis in allogeneic transplantation. Transplant Cell Ther 2021; 27:940–948.
Russo D, Schmitt M, Pilorge S, et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol 2024; 11:e127–e135.
Peters C, Schrappe M, von Stackelberg A, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol 2015; 33:1265–1274.
Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: long term outcomes. Immunol Res 2011; 49 (1–3):25–43.
Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367:1487–1496.
Zhang Z, Zhou X, Cheng Z, Hu Y. Peripheral blood stem cell transplantation vs. bone marrow transplantation for aplastic anemia: a systematic review and meta-analysis. Front Med (Lausanne) 2023; 10:1289180.
Ruiz-Argüelles GJ, Ruiz-Delgado GJ, González-Llano O, Gómez-Almaguer D. Haploidentical bone marrow transplantation in 2015 and beyond. Curr Oncol Rep 2015; 17:57.
Arcuri LJ, da Silva CC, da Costa LSS, et al. Costs of matched-sibling, unrelated, and Haploidentical hematopoietic cell transplantation and risk factors for greater financial burden - a Brazilian FACT-accredited single-center analysis. Ann Hematol 2022; 101:2507–2513.
van Gorkom G, Van Elssen C, Janssen I, et al. The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands. Eur J Haematol 2022; 108:327–335.
Brissot E, Labopin M, Ehninger G, et al. Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. Haematologica 2019; 104:524–532.
Al Malki MM, Yang D, Labopin M, et al. Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood Adv 2020; 4:2073–2083.
Santoro N, Labopin M, Giannotti F, et al. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol 2018; 11:55.
Versluis J, Labopin M, Ruggeri A, et al. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv 2017; 1:477–485.
Battipaglia G, Labopin M, Kröger N, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood 2019; 134:892–899.
Jimenez Jimenez A, Komanduri K, Brown S, et al. Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant. Blood Adv 2022; 6:4491–4500.
Gooptu M, Romee R, St Martin A, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood 2021; 138:273–282.
Mehta RS, Saliba RM, Ghanem S, et al. Haploidentical versus matched unrelated versus matched sibling donor hematopoietic cell transplantation with post-transplantation cyclophosphamide. Transplant Cell Ther 2022; 28:395.e1–395.e11.
Mussetti A, Kanate AS, Wang T, et al. Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas. Transplant Cell Ther 2023; 29:184.e1–184.e9.
Baron F, Labopin M, Tischer J, et al. Comparison of HLA-mismatched unrelated donor transplantation with posttransplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia. Bone Marrow Transplant 2022; 57:1657–1663.
Shaw BE, Jimenez-Jimenez AM, Burns LJ, et al. Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: follow-up from a national marrow donor program-sponsored prospective clinical trial. Transplant Cell Ther 2023; 29:208.e1–208.e6.
Ayuf F, Balduzzi A. Donor selection for adults and pediatrics. In: Carreras E, editor. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies.
Keating AK, Langenhorst J, Wagner JE, et al. The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia. Blood Adv 2019; 3:1118–1128.
Saglio F, Berger M, Spadea M, et al. Haploidentical HSCT with post transplantation cyclophosphamide versus unrelated donor HSCT in pediatric patients affected by acute leukemia. Bone Marrow Transplant 2021; 56:586–595.
Fierro-Pineda JC, Tsai HL, Blackford A, et al. Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias. Blood Adv 2023; 7:5639–5648.
Klein OR, Bonfim C, Abraham A, et al. Transplant for nonmalignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering. Cytotherapy 2023; 25:463–471.
Alotaibi H, Aljurf M, de Latour R, et al. Upfront alternative donor transplant versus immunosuppressive therapy in patients with severe aplastic anemia who lack a fully HLA-matched related donor: systematic review and meta-analysis of retrospective studies, on behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Transplant Cell Ther 2022; 28:105.e1–105.e7.
Dufour C, Veys P, Carraro E, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. Br J Haematol 2015; 171:585–594.
المشرفين على المادة: 0 (HLA Antigens)
تواريخ الأحداث: Date Created: 20240724 Date Completed: 20240926 Latest Revision: 20240926
رمز التحديث: 20240926
DOI: 10.1097/MOH.0000000000000831
PMID: 39046889
قاعدة البيانات: MEDLINE
الوصف
تدمد:1531-7048
DOI:10.1097/MOH.0000000000000831